Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Wenchyi Wang"'
Publikováno v:
Clinical and Experimental Nephrology
Background Tolvaptan is a vasopressin type 2 receptor antagonist and has been used to treat autosomal dominant polycystic kidney disease (ADPKD) since 2014. There has been limited real-world data on the safety and efficacy of tolvaptan. Methods This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f874880bc4252e2adec063de5904de86
http://europepmc.org/articles/PMC8460520
http://europepmc.org/articles/PMC8460520
Autor:
David H. Alpers, James H. Lewis, Christine M. Hunt, James W. Freston, Vicente E. Torres, Hui Li, Wenchyi Wang, Molly E. Hoke, Sharin E. Roth, Lucas Westcott-Baker, Alvin Estilo
Publikováno v:
American journal of kidney diseases : the official journal of the National Kidney Foundation.
Tolvaptan is associated with risk of drug-induced liver injury when used to treat autosomal dominant polycystic kidney disease (ADPKD). After this risk was described based on the clinical trials TEMPO 3:4 and TEMPO 4:4, additional data from the REPRI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43d6c18199374116e2b88ebeb5db7779
https://pubmed.ncbi.nlm.nih.gov/36191725
https://pubmed.ncbi.nlm.nih.gov/36191725
Publikováno v:
Cancer (0008543X); 10/25/2008 Supplement, Vol. 114, p420-421, 2p, 1 Chart